Table 1.
Baseline characteristics of study participants at initiation of nevirapine-based antiretroviral therapy
| Characteristic | Median (IQR) or N (%) |
|---|---|
| Age (yrs) | 36 (32–40) |
| Weight (kg) | 65 (54 – 70) |
| BMI (kg/m2) | 25.0 (22.3 – 28.2) |
| CD4 cell count (cells/μL) | 126 (79 – 154) |
| Plasma viral load (log10 copies/mL) | 5.54 (5.17 – 5.90) |
| Cervical viral load (log10 copies/mL) | 4.04 (3.42 – 4.60) |
| ALT levels (>ULN) | 11 (15.9) |
| Skin rash | 11 (15.9) |
| Plasma resistance (present) | 0 |
| Genital resistance (present) | 0 |
| ART regimen: d4T/3TC/NVP | 69 (100) |
BMI = body mass index, ALT = alanine aminotransferase, ULN = upper limit of normal, ART = antiretroviral therapy, NVP = nevirapine, d4T = stavudine, 3TC = lamivudine.